Clover Corporation Limited · ASX:CLV
Clover — Investor Presentation (March 2023)
13 slides from Clover's investor presentation, Mar 15, 2023
Slide 1: Managing Director Report
Managing Director Report 6 Months to 31 Jan 2023 15 March 2023
Slide 2: Vision, Values and Purpose Statement
Vision, Values and Purpose Statement Vision To optimise the health and development of adults, infants and children. Values Respect, Response, Responsibility Purpose In collaboration with key market participants, Clover develops customised high value nutritional ingredients that enhance the wellbeing
Slide 3: Record Results Half Year FY23
Record Results Half Year FY23 Total half year Revenue Operating Expenses $7.6m $44.4m up 49.5% on up 28.0% (1HFY22 $5.9m) with 1HFY22 $29.7m continued focus on R&D development, recruitment and NPAT $3.6m up customer engagement 81.1% on 1HFY22 $2.0m Clover has achieved revenue growth in Europ
Slide 4: Sales by Geography
Sales by Geography MEA EU European sales improved with the EU recovering from COVID-19 and returning to work. Middle East sales contributed growth with customers benefiting from higher female participation in work. Asia ANZ Sales into Asia have improved compared to the prior year. New busine
Slide 5: Half Year 2023 Results
Half Year 2023 Results Revenue increased 49.5% AUD million 4D Reported 4D Reported with projects recovering from 31 Jan 2023 31 Jan 2022 COVID-19 and infant formula Revenue $44.4 $29.7 customers building inventory EBITDA $5.7 $3.4 EBITDA was supported by resourcing of raw materials NPBT $5.0 $2.
Slide 6: Balance Sheet 31 January 2023
Balance Sheet 31 January 2023 AUD Reported Reported 31 Jan 2023 31 Jul 2022 Movement Cash balance remains $M $M $M strong $6.5m Cash 6.5 10.1 (3.6) Trade Receivables 17.6 19.6 (2.0) Trade receivables consistent on Inventories 41.1 36.0 5.1 comparative sales Total Current Assets 65.9 66.9 (1.0) v
Slide 7: An Update on Growth Platforms
An Update on Growth Platforms Focus on Infant Formula New New Product Market Development Development 6
Slide 8: Growth Platform: Successful Clinical trial - Premneo
Growth Platform Successful Clinical trial - Premneo Published in the New England Journal, the trial results demonstrated improved IQ for pre-term infants utilising our proprietary DHA emulsion product. The Medical Food product is branded Premneo which requires regulatory registration & approvals
Slide 9: Growth Platform: New products driving future growth
Growth Platform New products driving future growth Clover has achieved sales of Gelphorm, our proprietary emulsion product which allows UHT drinks to be fortified with Omega 3. Gelphorm is on trial with additional customers. The Company is progressed in the development of its next generation p
Slide 10: Growth Platform: Market development
Growth Platform Market development Europe & the Middle East have delivered growth through new customers and projects restarting post COVID-19. The Company has reinitiated customer engagement through visits and trade shows. Melody Dairies continues to be a key strategic investment providing div
Slide 11: Growth Platform: China provides new infant formula opportunities
Growth Platform Focus on Infant China provides new infant formula opportunities Formula 1HFY23 Revenues have been strengthened by customers building inventory in preparation for the new China GB standard. The China GB Standard requires infant formula manufacturers to hold a license to sell throu
Slide 12: 2HFY23 Outlook & Priorities
2HFY23 Outlook & Priorities Maintain the Heath & Safety focus on our employees, suppliers, customers and stakeholders Continued development of new products in food and nutraceutical applications leveraging our R&D capability Manage the inventory position to maintain supply and minimise cost
Slide 13: Disclaimer
Disclaimer The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe such restrictions. This